Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail.
Hiatt
Bonnie L
BL
Stanford University Medical Center, Stanford, California.
Ikeno
Fumaiki
F
Yeung
Alan C
AC
Carter
Andrew J
AJ
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D003609:Dactinomycin / Q000008:administration & dosage; D003864:Depression, Chemical; D006801:Humans; D015918:Infusion Pumps, Implantable; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology; D020123:Sirolimus / Q000008:administration & dosage / Q000494:pharmacology; D015607:Stents / Q000009:adverse effects
D020099:Coated Materials, Biocompatible; D003609:Dactinomycin; D017239:Paclitaxel; D020123:Sirolimus